Catalyst Awardee

Project Description

Response evaluation of cryoablation focal therapy for low-intermediate risk prostate cancer guided by a novel molecular imaging – PET/MR

Ming Liu, PhD; Yaqun Zhang; Min Chen; Chunmei Li; Zhi Yang; Hui Zhu; Wei Zhang; Xuan Wang; Huimin Hou; Miao Wang; Qiuxia Yan | Beijing Hospital
Competition Sponsor: Chinese Academy of Medical Sciences
Award year: 2021

Prostate cancer is the most common malignancies among men worldwide. and seriously affects the health and quality of life of elderly men. Radical treatment (radical surgery, radiotherapy) is still the standard treatment for low- to intermediate-risk prostate cancer, but the incidence of related complications such as erectile dysfunction, urinary incontinence, radiation proctitis is high, which greatly affect the quality of life of patients after treatment. The novel focal cryoablation has the potential to cure prostate cancer and preserve the function at the same time; however, cryotherapy is now guided by ultrasound which is not accurate enough to localize the lesion and guide the treatment. Moreover, there’s no standardized strategy to monitor recurrence currently, which might impact the certainty of safety and would limit the spread of this technique. PSMA PET / MR is a novel molecular imaging technology, which combines the high sensitivity and specificity of molecular imaging with the good tissue resolution of mp-MRI. It has the potential to become a novel imaging choice to guide focal therapy and to monitor postoperative recurrence. The purpose of this study is to confirm that PSMA PET/MR can be used as a reliable examination for evaluation of therapeutic effect and diagnosis of recurrence. Eventually, a standardized system of PSMA PET/MR guided cryoablation therapy and postoperative efficacy and recurrence monitoring will be established for the treatment of low- to intermediate-risk prostate cancer patients, ultimately extending the “healthy life span” of high quality in those patients.

Sign up for updates